Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders bought 33,531 call options on the stock. This represents an increase of approximately 180% compared to the typical daily volume of 11,957 call options.
In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,894 shares of company stock worth $317,139. Corporate insiders own 15.75% of the company's stock.
Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at $25,000. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $26,000. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after buying an additional 3,377 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.
Shares of NASDAQ RXRX traded up $0.73 during midday trading on Wednesday, reaching $7.61. 17,235,972 shares of the company were exchanged, compared to its average volume of 14,933,171. The stock has a fifty day simple moving average of $6.86 and a 200 day simple moving average of $6.94. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.97 billion, a P/E ratio of -5.00 and a beta of 0.85. Recursion Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.43) earnings per share. On average, research analysts forecast that Recursion Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.
RXRX has been the topic of several recent research reports. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus price target of $8.75.
Check Out Our Latest Research Report on RXRX
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.